We are live on
!
Find out more
SCM
Salem Capital Management Portfolio holdings
AUM
$126M
1-Year Est. Return
8.82%
This Fund
S&P 500
This Quarter
Est. Return
+3.97%
1 Year Est. Return
-8.82%
3 Year Est. Return
+32.26%
5 Year Est. Return
+45.09%
10 Year Est. Return
–
AUM
$173M
AUM Growth
-$4.41M
(-2.5%)
Cap. Flow
-$10.3M
Cap. Flow
% of AUM
-5.95%
Top 10 Holdings %
Top 10 Hldgs %
42.33%
Holding
68
New
2
Increased
15
Reduced
29
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bank of America
BAC
|
+$2.82M |
| 2 |
Corning
GLW
|
+$229K |
| 3 |
Bristol-Myers Squibb
BMY
|
+$219K |
| 4 |
ESRX
Express Scripts Holding Company
ESRX
|
+$209K |
| 5 |
Vodafone
VOD
|
+$199K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$4.21M |
| 2 |
Novartis
NVS
|
+$3.98M |
| 3 |
DD
Du Pont De Nemours E I
DD
|
+$3.22M |
| 4 |
AbbVie
ABBV
|
+$920K |
| 5 |
CVS Health
CVS
|
+$418K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.93% |
| 2 | Technology | 14.18% |
| 3 | Industrials | 13.46% |
| 4 | Consumer Staples | 10.46% |
| 5 | Energy | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Eli Lilly
LLY
$1.02T
| $478K | 0.28% |
6,067
+617
| +11% | +$46.5K |
|
52
Stryker
SYK
$125B
| $473K | 0.27% |
3,950
| – | – |
|
53
Southern Company
SO
$109B
| $469K | 0.27% |
8,750
| – | – |
|
54
Analog Devices
ADI
$179B
| $338K | 0.19% |
5,970
| – | – |
|
55
Duke Energy
DUK
$97.8B
| $309K | 0.18% |
3,602
| – | – |
|
56
Wells Fargo
WFC
$261B
| $289K | 0.17% |
6,110
| – | – |
|
57
RTX Corp
RTX
$290B
| $277K | 0.16% |
4,298
-183
| -4% | -$11.7K |
|
|
STR
58
DELISTED
QUESTAR CORP
STR
| $273K | 0.16% |
10,750
-150
| -1% | -$3.76K |
|
|
59
GSK
GSK
$104B
| $254K | 0.15% |
4,680
-79,988
| -94% | -$4.21M |
|
60
Sysco
SYY
$40.8B
| $254K | 0.15% |
5,000
| – | – |
|
61
Automatic Data Processing
ADP
$106B
| $248K | 0.14% |
2,700
| – | – |
|
62
Cintas
CTAS
$81.9B
| $245K | 0.14% |
10,000
-2,000
| -17% | -$46.1K |
|
|
63
Bristol-Myers Squibb
BMY
$133B
| $228K | 0.13% |
+3,100
| New | +$219K |
|
|
ESRX
64
DELISTED
Express Scripts Holding Company
ESRX
| $216K | 0.12% |
+2,845
| New | +$209K |
|
65
Caterpillar
CAT
$375B
| $205K | 0.12% |
2,700
| – | – |
|
66
Apple
AAPL
$4.54T
| – | – |
-8,300
| Closed | -$226K |
|
Similar funds
FFC
WC
SP
EVC
HGM
JSMC
RCM
DIV
Salem Capital Management's Q2 2016 Portfolio in Review
As of Q2 2016, Salem Capital Management held 68 positions worth $173M, down 2.5% from $178M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Salem Capital Management withdrew a net $10.3M in Q2 2016, closing 1 position and reducing 29 holdings. Its most notable exit was Apple, an estimated $226K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 25% a quarter earlier, followed by Technology and Industrials.
Against the trend, Salem Capital Management opened a new position in Bristol-Myers Squibb worth $228K.
- Salem Capital Management's largest Q2 2016 buy was Bristol-Myers Squibb: 3,100 shares worth $228K.
- Salem Capital Management added most to Bank of America in Q2 2016, an estimated $2.82M increase.
- Salem Capital Management's biggest Q2 2016 reduction was GSK, cutting an estimated $4.21M.
- Salem Capital Management fully exited Apple in Q2 2016, selling an estimated $226K.
- Salem Capital Management's ten largest holdings make up 42% of its $173M portfolio in Q2 2016.
- Salem Capital Management opened 2 new positions and closed 1 in Q2 2016.
- Salem Capital Management's portfolio value fell 2.5% quarter-over-quarter to $173M.
Based on Salem Capital Management's 13F filing for Q2 2016, filed 11 Jul 2016.